UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000063698
Receipt number R000072537
Scientific Title A study of the effects of intake of food ingredients on peripheral blood flow in healthy adults -Randomized, double-blind, placebo-controlled, parallel-group study-
Date of disclosure of the study information 2026/11/19
Last modified on 2026/11/18 12:01:21

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A study of the effects of intake of food ingredients on peripheral blood flow in healthy adults -Randomized, double-blind, placebo-controlled, parallel-group study-

Acronym

A study of the effects of intake of food ingredients on peripheral blood flow

Scientific Title

A study of the effects of intake of food ingredients on peripheral blood flow in healthy adults -Randomized, double-blind, placebo-controlled, parallel-group study-

Scientific Title:Acronym

A study of the effects of intake of food ingredients on peripheral blood flow

Region

Japan


Condition

Condition

None

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the effects of intake of food ingredients on peripheral blood flow.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Peripheral blood flow

Key secondary outcomes

Other circulatory parameters
Skin surface temperature
Related subjective evaluations
Blood biochemical analysis


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification

YES

Dynamic allocation

NO

Institution consideration


Blocking


Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Food

Interventions/Control_1

Intake of the test food for 6 weeks

Interventions/Control_2

Intake of the placebo food for 6 weeks

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

30 years-old <=

Age-upper limit

55 years-old >

Gender

Male and Female

Key inclusion criteria

(1) Men and women who are aged 30 years or older and under 55 years at the time of obtaining informed consent
(2) Individuals who are judged to be in good health by the principal investigator
(3) Individuals who experience coldness in their hands and feet in daily life
(4) Individuals who experience decreased vigor/vitality or fatigue in daily life
(5) Individuals who are able to visit the study site and undergo examinations on the designated examination dates
(6) Individuals who have received a sufficient explanation of the purpose and details of the study, have the capacity to consent, fully understand the study, voluntarily wish to participate, and are able to provide written informed consent to participate in the study
(7) Individuals who are deemed appropriate to participate in the study by the principal investigator

Key exclusion criteria

(1) Individuals who are receiving continuous drug treatment for any disease, or regularly using pharmaceutical or quasi-drug products for purposes other than disease treatment
(2) Individuals who have continuously used pharmaceutical or quasi-drug products for disease treatment within the past month
(3) Individuals who have a history or current diagnosis of diabetes, pulmonary, renal, hepatic, heart, serious gastrointestinal, or other serious disease
(4) Individuals who have symptoms of severe anemia
(5) Individuals who are at risk of allergy to study food ingredients, or who have a history of serious food or drug allergy
(6) Individuals who have a history of reactions to cold water or cold stimuli, such as urticaria, redness, itching, numbness, decreased blood pressure, or difficulty breathing, or who have cold urticaria or allergic reactions to cold stimuli
(7) Individuals who are breastfeeding, pregnant or possibly pregnant, or wish to become pregnant during the study
(8) Individuals who have a history or current diagnosis of drug or alcohol dependence, or who have a psychiatric disorder that may affect study participation
(9) Individuals who habitually consume excessive amounts of alcohol
(10) Individuals who have a smoking habit
(11) Individuals who have habitually engaged, within the past month, in moderate- or higher-intensity physical activity for 150 minutes or more per week, or in muscle-strengthening activities on 2 or more days per week
(12) Individuals whose BMI is less than 18.5 kg/m2 or 25.0 kg/m2 or higher
(13) Individuals who are currently using or have used antihistamines within the past month
(14) Individuals who have experienced or are expected to experience a life event that may have a significant psychological impact during the study period
(15) Individuals who have irregular lifestyles or dietary habits
(16) Individuals who are judged by a physician to have severe cold sensitivity accompanied by Raynaud's phenomenon or similar symptoms

Target sample size

140


Research contact person

Name of lead principal investigator

1st name Masahiko
Middle name
Last name Morita

Organization

Kirin Holdings Company, Limited

Division name

Institute of Health Sciences

Zip code

251-8555

Address

Shonan Health Innovation Park, 2-26-1, Muraoka-Higashi, Fujisawa, Kanagawa 251-8555, Japan

TEL

090-3063-2127

Email

Masahiko_Morita@kirin.co.jp


Public contact

Name of contact person

1st name Masanori
Middle name
Last name Numa

Organization

CPCC Company Limited

Division name

Clinical Planning Department

Zip code

103-0021

Address

4F Daiwa Building, 3-3-10 Nihonbashi-Hongokucho, Chuo-ku, Tokyo 103-0021, Japan

TEL

03-6225-9001

Homepage URL


Email

cpcc-contact@cpcc.co.jp


Sponsor or person

Institute

Kirin Holdings Company, Limited

Institute

Department

Personal name



Funding Source

Organization

Kirin Holdings Company, Limited

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Research Ethical Review Committee of Kirin Holdings Company, Ltd

Address

Nakano Central Park South, 4-10-2, Nakano, Nakano-ku, Tokyo, Japan

Tel

03-6837-4128

Email

02976_Ni@kirin.co.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

チヨダパラメディカルケアクリニック(東京都)Chiyoda Paramedical Care Clinic


Other administrative information

Date of disclosure of the study information

2026 Year 11 Month 19 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2026 Year 11 Month 12 Day

Date of IRB

2026 Year 11 Month 12 Day

Anticipated trial start date

2026 Year 12 Month 05 Day

Last follow-up date

2027 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

(Exclusion criteria continued)
(17) Women who have severe menstrual irregularities or severe physical or psychological symptoms associated with premenstrual syndrome (PMS)
(18) Individuals who are unable to avoid exposure to strong direct sunlight, such as through sunbathing, during the study
(19) Individuals who currently or within the past 3 months have habitually consumed supplements, health foods, foods for specified health uses, foods with functional claims, or similar products
(20) Individuals who are currently using or have used within the past 3 months pharmaceutical products claiming beneficial effects on blood flow, blood pressure, or cold sensitivity
(21) Individuals who habitually consume large amounts of specific foods or beverages that may affect study results
(22) Individuals who habitually consume large amounts of caffeine
(23) Individuals who are employed by a company involved in the development, manufacture, or sale of functional foods
(24) Individuals who are currently participating in, scheduled to participate in, or within 4 weeks after completion of another food intake, pharmaceutical use, or cosmetic or pharmaceutical application study
(25) Individuals who are aware that they are infected with hepatitis B or C virus or HIV
(26) Individuals who refuse to disclose their biological sex
(27) Individuals who have donated blood components or 200 mL of whole blood within 1 month before the start of the study
(28) Individuals who have donated 400 mL of whole blood within 3 months before the start of the study
(29) Individuals who are otherwise judged by the principal investigator or sub-investigator to be inappropriate for participation in the study


Management information

Registered date

2026 Year 11 Month 19 Day

Last modified on

2026 Year 11 Month 18 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000072537